BioCardia Inc logo

BCDA - BioCardia Inc News Story

$4.01 -0.3  -7.6%

Last Trade - 12/04/21

Micro Cap
Market Cap £47.7m
Enterprise Value £32.1m
Revenue £106k
Position in Universe 5462nd / 6841

BioCardia Issued New U.S. Patent for Technology that Enhances Control for Cardiac Therapies

Wed 30th December, 2020 1:30pm
For best results when printing this announcement, please click on link below:

SAN CARLOS, Calif., Dec. 30, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc.
( [Nasdaq:
BCDA] a leader in the development of comprehensive solutions for
cardiovascular regenerative therapies, today announced the issuance of U.S.
Patent No: 10,874, 831 for “Devices and Methods for Accessing the
Vasculature of a Patient” that further protects the Helix™ Biotherapeutic
Delivery System
( and
enhances its cell therapy delivery capabilities.

This patent covers a steerable design intended to provide uniform bending
rigidity in all orientations. This uniform bending rigidity is expected to
significant enhance physician control in tortuous anatomy. The patented
technology is incorporated in the Company’s recently approved Morph DNA and
AVANCE steerable catheter offerings. The advances also are expected to
strengthen the Company’s clinical stage biotherapeutic programs in heart
failure and chronic myocardial ischemia. 

“We continue to believe that delivery is critically important to successful
biotherapeutic treatment. You can have a promising cell therapy, but if
sub-par delivery doesn’t facilitate biologic retention by the heart or has a
poor safety profile, it can cause a therapy to fail,” said BioCardia CEO
Peter Altman, Ph.D. “At BioCardia, we have always recognized the important
role delivery plays in the overall success of our therapeutics and in their
promise to improve the lives of millions of patients with heart disease. This
additional patent protection for technology to enhance physician control for
all steerable catheter systems, is anticipated to have value and impact beyond
the scope of our biotherapeutic programs, initially through our Avance product

About BioCardia®

BioCardia, Inc.
headquartered in San Carlos, California, is developing regenerative biologic
therapies to treat cardiovascular and respiratory disease. CardiAMP autologous
and Neurokinin-1 Receptor Positive allogenic cell therapies are the
Company’s biotherapeutic platforms in clinical development. The Company's
products include the Helix Biotherapeutic Delivery System and its steerable
guide and sheath catheter portfolio. BioCardia also partners with other
biotherapeutic companies to provide its Helix system and clinical support for
their programs studying therapies for the treatment of heart failure, chronic
myocardial ischemia and acute myocardial infarction. For more information,

Forward Looking Statements:
This press release contains forward-looking statements that are subject to
many risks and uncertainties. Forward-looking statements include statements
regarding our intentions, beliefs, projections, outlook, analyses or current
expectations. These forward-looking statements include, without limitation,
statements relating to the impact of our catheter technologies on procedural
control and safety as well as the likelihood of success and the value of our
clinical cell therapy programs.

We may use terms such as “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should,” “approximately” or other words that
convey the uncertainty of future events or outcomes to identify these
forward-looking statements. These forward-looking statements reflect our view
as of the time such statement is made and are not guarantees of future
performance or developments. You are strongly cautioned that reliance on any
forward-looking statements involves known and unknown risks and uncertainties.
Actual results and events may differ materially from information contained in
the forward-looking statements as a result of a number of factors including,
among others, the inherent uncertainties associated with developing new
products or technologies, regulatory approvals, unexpected expenditures, the
ability to raise the additional funding needed to continue to pursue
BioCardia’s business and product development plans and overall market
conditions. As a result of these factors, we cannot assure you that the
forward-looking statements in this presentation will prove to be accurate.
 Additional factors that could materially affect actual results can be found
in our documents filed with the SEC, including our recent filings on Form 8-K,
Form 10-K and Form 10-Q, particularly any statements under the caption
entitled “Risk Factors” Therein.” BioCardia expressly disclaims any
intent or obligation to update these forward-looking statements, except as
required by law.

David McClung, Chief Financial Officer
(650) 226-0120

Michelle McAdam, Chronic Communications, Inc.
(310) 545-6654



GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.